| Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. | |
| | |
MedLine Citation:
|
PMID: 17135738 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. OBJECTIVE: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. METHODS: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). RESULTS: There was a trend towards a difference between treatments from the overall treatment effect for the percentage of satisfactory responses for each patient during the study (p = 0.071). This appeared to be due to the comparison of the two-compound and calcipotriol groups (p = 0.025). CONCLUSION: There was a trend towards the efficacy of the two-compound product used for up to 52 weeks being better than that of 4 weeks of the two-compound product followed by 48 weeks of calcipotriol. |
| | |
Authors:
|
K Kragballe; J Austad; L Barnes; A Bibby; M de la Brassinne; F Cambazard; C Fleming; H Heikkilä; Z Williams; J Peyri Rey; A Svensson; J Toole; G Wozel |
Related Documents
:
|
2757958 - Relapse rates in moderately severe chronic psoriasis treated with cyclosporin a. 18360628 - Acne phototherapy with a 1450-nm diode laser: an open study. 10721828 - Topical photodynamic therapy for localized scleroderma. 16854758 - Predictors of treatment choices and associated outcomes in actinic keratoses: results f... 20639828 - Evaluation of bacterial colonization and bacteriuria secondary to internal ureteral stent. 16872028 - The outcome of direct current cardioversion (dcc) for the treatment of atrial fibrillat... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Dermatology (Basel, Switzerland) Volume: 213 ISSN: 1018-8665 ISO Abbreviation: Dermatology (Basel) Publication Date: 2006 |
Date Detail:
|
Created Date: 2006-11-30 Completed Date: 2007-02-16 Revised Date: 2009-10-08 |
Medline Journal Info:
|
Nlm Unique ID: 9203244 Medline TA: Dermatology Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 319-26 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2006 S. Karger AG, Basel. |
Affiliation:
|
Marselisborg Hospital, Aarhus, Denmark. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents
/
administration & dosage,
therapeutic use* Betamethasone / administration & dosage, analogs & derivatives*, therapeutic use Calcitriol / administration & dosage, analogs & derivatives*, therapeutic use Dermatologic Agents / administration & dosage, therapeutic use* Double-Blind Method Drug Combinations Female Follow-Up Studies Humans Male Middle Aged Patient Satisfaction Psoriasis / drug therapy* Safety Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Dermatologic Agents; 0/Drug Combinations; 0/betamethasone dipropionate, calcipotriol drug combination; 112965-21-6/calcipotriene; 32222-06-3/Calcitriol; 378-44-9/Betamethasone; 5593-20-4/betamethasone-17,21-dipropionate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in cl...
Next Document: Psoriasis therapy in real life: the need for registries.